Luke O’Neill, the well-known immunologist, has joined the board of the fledgling Poolbeg Pharma which is preparing for a stock market launch in coming weeks.
Poolbeg Pharma is a newly launched spin-off of Open Orphan, the life sciences business co-founded by veteran financier Cathal Friel, and will specialise in developing drugs to treat infectious diseases.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).